Prevention of relapse of Crohn's disease.
Until a cure for Crohn's disease(s) is found, strategies that prolong the time spent in remission offer the greatest hope for reducing the morbidity and significant social costs associated with the disease. Medical therapy to date has been disappointing, and the search for a safe, effective therapy that could be offered at low cost continues. The aminosalicylates, so effective in ulcerative colitis, have shown, at best, minimal efficacy in maintaining remission in Crohn's disease. Conventional corticosteroids are not effective, and any reduction in time to relapse for budesonide-treated patients is measured in weeks not months. Azathioprine, 6-mercaptopurine, and methotrexate are effective in maintaining remission, but all three have significant side effects. Antibiotics may have a role to play. Biological therapy may be considered, but the issues of cost and long-term safety require evaluation. Future studies should segregate patients into two groups, those with a medically induced remission and patients whose concern is the prevention of postoperative recurrence.
Sutherland
L R
LR
Department of Community Health Sciences, University of Calgary, Alberta, Canada. lsutherl@ucalgary.ca
D019819:Budesonide / Q000627:therapeutic use; D003424:Crohn Disease / Q000517:prevention & control*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D019804:Mesalamine / Q000627:therapeutic use; D055502:Secondary Prevention
D005765:Gastrointestinal Agents; D019804:Mesalamine; D019819:Budesonide